Abbisko Cayman Limited · HKEX:2256
Abbisko Cayman — Abbisko Therapeutics — H1 2022 Earnings Presentation
18 slides from Abbisko Cayman's earnings presentation, August 2022
Slide 1: Abbisko Therapeutics 1H 2022 Interim Results Presentation
Abbisko Therapeutics 1H 2022 Interim Results Presentation August 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements The accuracy of Abbisko’s estimates regarding expenses, future revenue, future expenditures and needs for and ability to obtain additional financing, Abbisko’s ability to obtain and maintain intellectual property protection for its product candidates and approved products,
Slide 3: Agenda
Agenda Opening Remarks Dr. Yao-Chang Xu Program Update Dr. Zhui Chen Dr. Jing Ji Financial Update Dr. Zidong Zhang Closing Remarks Dr. Yao-Chang Xu Q&A 2
Slide 4: Opening Remarks
OPENING REMARKS Dr. Yao-Chang Xu 3
Slide 5: Abbisko at A Glance
Abbisko at A Glance GLOBAL CLINICAL DEVELOPMENT EFFICIENT INTERNAL CAPABILITIES DISCOVERY ENGINE 6 Assets in clinical stage 10 PCCs discovered since 2017 10+ Clinical trials in four countries and regions ~2 PCCs delivered per year on average STEADY ORGANIZATIONAL SUCCESSFUL IPO & EXPANDED BUSINESS G
Slide 6: Major Achievements Were Accomplished in All Aspects during 1H 2022
Major Achievements Were Accomplished in All Aspects during 1H 2022 Talent Expansion Research and Development • +32 new employees, with 25 new hires for • +3 new IND approvals R&D related roles • +1 new program added to the pipeline • CFO – Dr. Zidong Zhang • Executive Director of BD – Dr. Hua Jiang
Slide 7: We Maintained Business Operation and Continued to Make Progress with Minimized Impact from COVID
We Maintained Business Operation and Continued to Make Progress with Minimized Impact from COVID Lockdown during 1H 2022 Entered into Entered into ABSK091 ABSK043 New Chief New Executive global co- collaboration with received Orphan received China Financial Officer Director of discovery Beigene for
Slide 8: Enhanced Business Development Exemplified by Global Co-Discovery Collaboration with Eli Lilly
Enhanced Business Development Exemplified by Global Co- Discovery Collaboration with Eli Lilly and Company INNOVATION GLOBOLIZATION A new collaboration model Potential financial benefits • Abbisko eligible to receive up to US$258m in • A worldwide co-discovery collaboration on a potential milestone
Slide 9: Program Update
PROGRAM UPDATE Dr. Zhui Chen Dr. Jing Ji 8
Slide 10: We Continued to Grow and Advance Our Pipeline
We Continued to Grow and Advance Our Pipeline Assets Target Indication Mono/Combo Discovery IND Enabling Phase I/Ia POC (i) Pivotal Partner Rights Monotherapy ABSK011 FGFR4 FGF19+ HCC Global Combination therapy (ii) RMS and other ABSK012 FGFR4 mutant solid tumors Monotherapy Global Monotherapy Partn
Slide 11: IND-Enabling Studies Are Ongoing for Multiple Pre-Clinical Programs
IND-Enabling Studies Are Ongoing for Multiple Pre-Clinical Programs Recent Asset MoA Differentiation Potential indication and market size (i) development • Next-generation pan-FGFR small molecule • Urothelial cancer, cholangiocarcinoma, inhibitor that overcomes mutations resistant endometrial cancer
Slide 12: Notable Progress Has Been Achieved for All Clinical Trials
Notable Progress Has Been Achieved for All Clinical Trials Where we started Where we are January June now 2022 180mg QD cohort (dose 180mg QD cohort for expansion): completed dose expansion, Continuous patient enrollment for 180mg QD cohort Mono 320mg QD cohort (dose patient enrollment Explora
Slide 13: Notable Progress Has Been Achieved for All Clinical Trials (cont'd)
Notable Progress Has Been Achieved for All Clinical Trials (cont’d) Where we started Where we are January June now 2022 Patient enrollment completed for global Ph III Ph III trial ongoing by X4 Ph III trial ongoing Mono trial in WHIM, led by ABSK081 partner X4 CXCR4 Ph Ib/II trial in TNBC Cont
Slide 14: Financial Update
FINANCIAL UPDATE Dr. Zidong Zhang 13
Slide 15: We Maintained Robust Financial Position to Support Future Business Growth
We Maintained Robust Financial Position to Support Future Business Growth Strong cash RMB2,497m (~US$372m) cash and bank balances to fund business position activities with no near-term fund-raising pressure • Cash burn of roughly US$20m in 1H 2022 Disciplined financial • Committed to operational eff
Slide 16: Closing Remarks
CLOSING REMARKS Dr. Yao-Chang Xu 15
Slide 17: We Maintain Our Previous Guideline and Expect First Wave of Clinical PoC Data in 2H 2022
We Maintain Our Previous Guideline and Expect First Wave of Clinical Proof-of-Concept Data in 2H 2022 Pipeline Target Clinical trial Stage Event 1H 2022 2H 2022 1H 2023 Clinical candidates Target Actual 2L HCC, mono Phase Ib Preliminary POC readout ABSK011 FGFR4 1L/2L HCC, combo Phase II Preliminary
Slide 18: Thank You
Thank You 9